| 31.92 1.13 (3.67%) | 10-20 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 39.91  |
1-year : | 42.95 |
| Resists | First : | 34.17 |
Second : | 36.77 |
| Pivot price | 31.56 |
|||
| Supports | First : | 29.95 | Second : | 24.92 |
| MAs | MA(5) : | 30.67 |
MA(20) : | 32.05 |
| MA(100) : | 36.5 |
MA(250) : | 33.94 |
|
| MACD | MACD : | -1.5 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 27.6 |
D(3) : | 16.4 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 43 | Low : | 27.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IBRN ] has closed below upper band by 41.0%. Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.96 - 32.09 | 32.09 - 32.21 |
| Low: | 31.57 - 31.71 | 31.71 - 31.85 |
| Close: | 31.69 - 31.92 | 31.92 - 32.13 |
The iShares Neuroscience and Healthcare ETF (IBRN) aims to mirror the financial performance of a particular index. This index consists of companies, both domestically in the U.S. and from other countries, that are expected to benefit from new discoveries and the overall growth in the field of neuroscience.
Sat, 17 Oct 2026
The Technical Signals Behind (IBRN) That Institutions Follow - Stock Traders Daily
Sat, 26 Sep 2026
(IBRN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Wed, 16 Sep 2026
Trading the Move, Not the Narrative: (IBRN) Edition - Stock Traders Daily
Thu, 27 Aug 2026
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now - TradingView
Thu, 13 Aug 2026
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - Benzinga
Fri, 24 Nov 2023
HRTS ETF Price and Chart — NASDAQ:HRTS - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|